Clinical Trials Logo

Clinical Trial Summary

Critically ill patients who are mechanically ventilated may require prolonged administration of sedatives and analgesics. Their prolonged use has been associated with withdrawal symptoms upon rapid weaning in critically ill patients. These withdrawal symptoms may be associated with adverse clinical outcomes. Although well studied in the paediatric population, little is known about the epidemiology, risk factors and optimal screening methods in adults. Studying this problem is essential as we strive to develop proper weaning strategies.

Methods: Prospective observational two-center study in critically ill adult patients Objectives: 1) Describe the incidence of iatrogenic withdrawal of sedatives and analgesics in critically ill adult patients and 2) Evaluate the performance of screening tools assessing withdrawal that were developed for the paediatric patient in the adult population.


Clinical Trial Description

The objectives of the study are: 1) to describe the incidence of iatrogenic withdrawal of sedatives and analgesics in critically ill adult patients and; 2) Validate screening tools for withdrawal in the adult population.

Hypothesis

1. Symptoms of iatrogenic benzodiazepines and opioids withdrawal occur commonly in mechanically ventilated patients exposed to high doses and/or prolonged infusions and who are rapidly weaned from these therapies.

2. The scales for benzodiazepine and narcotic withdrawal detection used in paediatrics population correlate well with the DSM V diagnosis of withdrawal in an adult ICU population

3. Major risk factors for withdrawal symptoms include longer duration of therapy and higher doses and admission for a medical condition (MICU)

Methods

A prospective multicenter observational study will be carried out in two University-affiliated hospital intensive care units (Hôpital du Sacré-Coeur and Montreal General Hospital). All mechanically ventilated ICU patients receiving continuous infusions of benzodiazepines and/or opioids for more than 96 hours will be prospectively screened daily for withdrawal symptoms by an intensivist. Withdrawal symptoms for opioid and benzodiazepines will be identified using the DSM-V criteria. Patients with moderate to severe head trauma, a severe neurological disease, or prior to admission substance abuse (significant alcohol, illicit or prescription drugs) will be excluded. We will also exclude patients with a regularly prescribed chronic opioid or benzodiazepine use prior to ICU admission. Risk factors for withdrawal including type of agents exposed, dosing, duration of exposure, weaning of agents, organ dysfunction, age, gender, smoking, severity of disease and admission diagnosis will be prospectively collected. The Withdrawal Assessment Tool-1 (WAT-1), a screening tools validated in the paediatric population, will also be administered daily. The criterion validity of this screening tool will be compared to the DSM-V criteria. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02318290
Study type Observational
Source Hopital du Sacre-Coeur de Montreal
Contact
Status Completed
Phase N/A
Start date January 2015
Completion date December 2015

See also
  Status Clinical Trial Phase
Completed NCT00114439 - Lithium Cannabis Withdrawal Study Phase 2
Completed NCT00980044 - Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Phase 2/Phase 3
Completed NCT02643355 - Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED N/A
Completed NCT02782156 - Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT N/A
Recruiting NCT00792415 - Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool N/A
Completed NCT02431728 - The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Phase 1/Phase 2
Completed NCT00695864 - Effect of Ondansetron for Withdrawal Symptoms N/A
Active, not recruiting NCT02951793 - Abuse and Addiction in ICU
Completed NCT02108626 - Electronic Cigarettes in Daily Dependent Smokers Phase 4
Recruiting NCT04917185 - EA for PAAS: A pRCT N/A
Completed NCT02801357 - Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Phase 1
Completed NCT01362959 - Nicotine Replacement Therapy in the Intensive Care Unit Phase 4
Completed NCT00992979 - Therapeutic Massage to Manage Withdrawal Related Anxiety Phase 2
Completed NCT02825459 - Does Abstinence From E-cigarettes Produce Withdrawal Symptoms? N/A
Completed NCT00900900 - The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers Phase 2
Completed NCT00032968 - Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Phase 3
Completed NCT03374722 - Opioid Withdrawal Symptoms in Critically Ill Patients
Completed NCT03435614 - Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Completed NCT00570219 - The Effect of Valproate on Benzodiazepine Withdrawal Severity N/A
Completed NCT00367874 - Treatment of Polydrug-Using Opiate Dependents During Withdrawal Phase 4